KRISHZYME™ Heparin Factor IIa Assay Kit

Chromogenic assay for testing Heparins (UFH) in purified systems by measurement of Factor IIa inhibition, in compliance with EP Pharmacopoeia. About the kit: Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity, Recovery rates are between 85 - 115%, Ready to use with a standard protocol with break-apart pre-coated wells, Validated as per US FDA guidelines for Bioassays, Optimized for matrix effects to ensure higher sensitivity, Shelf life: 1 year. The inhibitory effect of Anti-Thrombin III (AT-III) on thrombin (Factor IIa) and other coagulation serine proteases in plasma is increased several thousand-fold by heparin. This inhibition accounts for the anticoagulant effect of heparin. The quantitative determination of heparin levels by the measurement of their Anti-IIa activity is a necessary tool for monitoring treatment efficacy. Unfractionated heparin (UFH) catalyzes both reactions equally. The Factor IIa inhibition test is the most useful assay covering the widest variety of heparin preparations. In the assay, the rate of Factor IIa inhibition is directly proportional to the heparin concentration since both Factor IIa and AT-III are in excess. The residual factor IIa activity is inversely proportional to the heparin concentration.